Mark McPhail is a Reader in Experimental Medicine and Honorary Consultant in Liver Intensive Care and Hepatology. He graduated with a PhD in Physics from Strathclyde University and then Medicine and Surgery from Glasgow University. He is interested in immunometabolism in liver failure syndromes and how lipid derangement affects innate immunity. He also has a keen interest in statistical methods and outcome research and is the Chief Scientific Investigator of the BOPPP (Betablockers or Placebo in Portal Hypertension) study. His group is based in the Insitute of Liver Studies at Denmark Hill and he collaborates with Imperial College and the United States Acute Liver Failure Study Group.